BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Jakobi K, Beyer S, Koch A, Thomas D, Schwalm S, Zeuzem S, Pfeilschifter J, Grammatikos G. Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro. Int J Mol Sci 2020;21:E2409. [PMID: 32244391 DOI: 10.3390/ijms21072409] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Liu L, Jiang H, Pan H, Zhu X. LncRNA XIST promotes liver cancer progression by acting as a molecular sponge of miR-200b-3p to regulate ZEB1/2 expression. J Int Med Res 2021;49:3000605211016211. [PMID: 34018840 DOI: 10.1177/03000605211016211] [Reference Citation Analysis]
3 Pinato DJ. Shifting paradigms in the systemic management of hepatocellular carcinoma. Lancet Gastroenterol Hepatol 2020;5:883-5. [PMID: 32941832 DOI: 10.1016/S2468-1253(20)30250-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int 2021;41:598-607. [PMID: 33188713 DOI: 10.1111/liv.14731] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi FG, Rovesti G, Negrini G, Orsi G, Renzulli M, Piscaglia F. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol 2019;71:1175-83. [PMID: 31449860 DOI: 10.1016/j.jhep.2019.08.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
6 Yoon JK, Choi JY, Rhee H, Park YN. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Eur Radiol 2022. [PMID: 35258675 DOI: 10.1007/s00330-022-08643-4] [Reference Citation Analysis]
7 Lanza E, Masetti C, Messana G, Muglia R, Pugliese N, Ceriani R, Lleo de Nalda A, Rimassa L, Torzilli G, Poretti D, D'Antuono F, Politi LS, Pedicini V, Aghemo A; Humanitas HCC Multidisciplinary Group. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. PLoS One 2020;15:e0232371. [PMID: 32555707 DOI: 10.1371/journal.pone.0232371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ochi M, Kamoshida T, Araki M, Ikegami T. Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment. World J Gastroenterol 2021; 27(32): 5424-5437 [PMID: 34539142 DOI: 10.3748/wjg.v27.i32.5424] [Reference Citation Analysis]
9 Mohr R, Tacke F. Therapie des hepatozellulären Karzinoms – eine neue Dekade? Drug Res (Stuttg) 2021;71:S22-3. [PMID: 34788884 DOI: 10.1055/a-1606-5955] [Reference Citation Analysis]
10 Hamada T, Yano K, Wada T, Imamura N, Hiyoshi M, Kondo K, Nanashima A. Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy. World J Surg 2020;44:2770-6. [PMID: 32318792 DOI: 10.1007/s00268-020-05527-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kim HI, Jang JK, Lim J, Chang S, An J, Kang HJ, Song GW, Lee SG, Kim SY, Shim JH. Hepatocyte-Specific Magnetic Resonance Imaging-Based Assessment of Indeterminate Hepatic Nodules in the Liver Transplant Evaluation of Patients With Cirrhosis. Liver Transpl 2020;26:359-69. [PMID: 31756026 DOI: 10.1002/lt.25684] [Reference Citation Analysis]
13 Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J (Engl) 2021;134:2911-21. [PMID: 34855640 DOI: 10.1097/CM9.0000000000001888] [Reference Citation Analysis]
14 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Reference Citation Analysis]
15 Ferrer-Fàbrega J, Forner A. Is downstaging a reliable strategy for expanding criteria for liver transplantation in hepatocellular carcinoma? Lancet Oncol 2020;21:867-9. [PMID: 32615100 DOI: 10.1016/S1470-2045(20)30333-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lin C, Kuo JC, Li D, Koenig AB, Pan A, Yan P, Bai X, Lee RJ, Ghoshal K. AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells. Front Cell Dev Biol 2022;10:853652. [DOI: 10.3389/fcell.2022.853652] [Reference Citation Analysis]
17 Xu G, Bu S, Wang X, Ge H. MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1. Int J Radiat Biol 2021;:1-7. [PMID: 34623217 DOI: 10.1080/09553002.2021.1987561] [Reference Citation Analysis]
18 Mai Q, Sheng D, Chen C, Gou Q, Chen M, Huang X, Yin H, Chen X, Chen Z. Steroid 5 alpha-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC). Aging (Albany NY) 2020;12:25395-411. [PMID: 33229626 DOI: 10.18632/aging.104142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer 2022;10:e004205. [PMID: 35710293 DOI: 10.1136/jitc-2021-004205] [Reference Citation Analysis]
20 Moazzami B, Majidzadeh-A K, Dooghaie-Moghadam A, Eslami P, Razavi-Khorasani N, Iravani S, Khoshdel A, Shahi F, Dashti H, Mehrvar A, Nassiri Toosi M. Cholangiocarcinoma: State of the Art. J Gastrointest Cancer 2020;51:774-81. [PMID: 32157571 DOI: 10.1007/s12029-020-00390-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
21 Lashen SA, Elshafei MM, Hablass FH, Alsayed EA, Hassan AA. Liver stiffness as a predictor of hepatocellular carcinoma behavior in patients with hepatitis C related liver cirrhosis. Hepatobiliary Pancreat Dis Int 2020;19:22-8. [PMID: 31831335 DOI: 10.1016/j.hbpd.2019.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T, Horhat A, Spârchez M, Dufour JF. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? World J Gastrointest Oncol 2021; 13(12): 1896-1918 [DOI: 10.4251/wjgo.v13.i12.1896] [Reference Citation Analysis]
23 Huang X, Lai Y, Yao N, Cui Y, Yu X, Cai Z, Tang Y, Huang Y, Zeng J. High expression of microRNA-1266 in hepatocellular carcinoma is associated with poor prognosis of patients and biological cell growth. Oncol Lett 2021;21:347. [PMID: 33747204 DOI: 10.3892/ol.2021.12608] [Reference Citation Analysis]
24 Ma D, Wang J, Liu L, Chen M, Wang Z. Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study. BMC Cancer 2020;20:936. [PMID: 32993568 DOI: 10.1186/s12885-020-07447-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]